Fu, Jie,Hanes, Justin,Kays, Joshua,Yu, Yun,Yang, Ming,Cleland, Jeffrey,Stark, Walter,Xu, Qingguo,Yang, Jin
申请号：
NZ73313015
公开号：
NZ733130A
申请日:
2015.12.15
申请国别(地区):
NZ
年份:
2018
代理人:
摘要：
Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or its analog or a pharmaceutically acceptable salt thereof. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or prevent a disease or disorder in or on the eye of a patient associated with vascularization, such as corneal neovascularization and acute macular degeneration. Upon administration, the sunitinib or its analog or salt is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity.
